Use access key #2 to skip to page content.

IBDvalueinvestin (99.66)

FDA Approves KALYDECO™ (ivacaftor), the First Medicine to Treat the Underlying Cause of Cystic Fibrosis

Recs

1

January 31, 2012 – Comments (0) | RELATED TICKERS: VRTX , PFE , BMY

FDA Approves KALYDECO™ (ivacaftor), the First Medicine to Treat the Underlying Cause of Cystic Fibrosis Business Wire (Tue 1:33PM EST)

 

I personally just loaded up with shares of VRTX on halt lift.

0 Comments – Post Your Own

Featured Broker Partners


Advertisement